Otsu/Shiga, Japan – October 27, 2015 - Takara Bio Inc. announced that it signed licensing agreement with Broad Institute (Cambridge, MA, the U.S.), involving patents on genome editing owned by the Institute, Massachusetts Institute of Technology and Harvard University, in world-wide research field.
Genome editing is one of genetic engineering techniques, involving destruction or insertion of target genes. It is widely used not only in basic research fields, but also in applied research fields including regenerative medicine. This time, Takara Bio acquired licensing agreement on genome editing based on CRISPER/Cas9 system (the U.S. patent number 8697359, and other patents), a rapidly spreading technique because of its excellent operability and efficiency compared to existing techniques in this field.
Takara Bio group is focused on developing new products and services in genome editing field with growth potential, and expands its earnings.
The Eli and Edythe L. Broad Institute of MIT and Harvard
|Head office||7 Cambridge Center, Cambridge, MA 02142, US|
|Broad Institute is engaged in researches in medicine and biology, as a research facility jointly operated by Harvard University and Massachusetts Institute of Technology.|